Scientific Program
08:00
Registration
09:00-09:10
Welcome & Opening Remarks
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Prof. Dr. Caroline Robert, France | Congress Chairs
09:10-10:40
Session 1: Prevention & New Screening Technology
09:10-09:35
Primary Prevention: Skin Screening Yes or No?
Susana Puig
Hospital Clínic Barcelona, Spain
09:35-09:40
Discussion/Q&A
09:40-10:05
Advances in Digitalizing Diagnostics From Dermatoscopy to (Whole Body) Photography
10:05-10:10
Discussion/Q&A
10:10-11:25
Session 2: Risk of Relapse Stratification & Developments in the Surgical Management of Melanoma
10:10-10:20
Short Overview: Reduction Of Surgical Interventions in Melanoma Management
Alexander M.M. Eggermont
Utrecht University, Netherlands
10:20-10:25
Discussion/Q&A
10:25-10:50
Results of the USA Phase 3 Trial Merlin_001
10:50-10:55
Discussion/Q&A
10:55-11:20
Risk Stratification by Gene Expression Profiling of Primary Melanomas: to which degree can it replace SLNB?
Teresa Amaral
University of Tübingen, Germany
11:20-11:25
Discussion/Q&A
11:25-11:45
Coffee Break, Poster Viewing & Visit the Exhibition
11:45-12:15
Session 3: Short Presentations Young Investigators
12:15-13:15
Industry Sponsored Symposium
13:15-13:45
Lunch Break, Poster Viewing & Visit the Exhibition
13:45-14:30
Session 4: From Adjuvant To Neoadjuvant Strategies
13:45-13:55
Short Update Adjuvant Therapies: Successes and Failures
Alexander M.M. Eggermont
Utrecht University, Netherlands
13:55-14:00
Discussion/Q&A
14:00-14:15
Neoadjuvant Therapies: Where do we go after SWOG1801 and NADINA?
14:15-14:20
Discussion/Q&A
14:20-14:30
Neoadjuvant Revolutions: What can we learn form other tumors?
14:30-15:45
Session 5: What's New in Non Melanoma Skin Cancers
14:30-14:50
CutSCC and BCC
14:50-14:55
Discussion/Q&A
14:55-15:15
Merkel Cell Carcinoma
15:15-15:20
Discussion/Q&A
15:20-15:40
Kaposi Sarcoma
Celeste Lebbé
Saint-Louis Hospital, Paris, France
15:40-15:45
Discussion/Q&A
15:45-16:15
Coffee Break, Poster Viewing & Visit the Exhibition
16:15-16:40
Session 6: What's New In Uveal Melanoma
16:15-16:35
Advanced and Adjuvant
Sophie Piperno-Neumann
Institut Curie, Paris, France
16:35-16:40
Discussion/Q&A
16:40-17:10
Session 7: Management and Outcome of Immune Related Adverse Events
16:40-17:05
Management and Outcome of Immune Related Adverse Events
Karijn Suijkerbuijk
UMC Utrecht Cancer Center, Netherlands
17:05-17:10
Discussion/Q&A
17:10-18:00
Session 8: Short Presentations Young Investigators
18:00
End of Day One
08:30
Registration
09:00-11:30
Session 9: What's New in Advanced Melanoma
09:00-09:20
Role Of Liquid Biopsies in Decision Making in Adjuvant and Advanced Melanoma Setting
Christoffer Gebhardt
University Medical Center Hamburg-Eppendorf (UKE), Germany
09:20-09:25
Discussion/Q&A
09:25-09:45
Emerging Role of ctDNA in Melanoma Management
Paul Lorigan
The Christie NHS Foundation Trust, UK
09:45-09:50
Discussion/Q&A
09:50-10:10
Biomarkers And Decision-Making Monotherapy Or Combination Therapies/Schedules In Advanced Melanoma: Conclusions Of Dreamseq-Secombit And Ebin Trials
Caroline Robert
Gustave Roussy Cancer Campus, Paris, France
10:10-10:15
Discussion/Q&A
10:15-10:35
What's New in Advanced Melanoma 1st Line - NEW DOUBLETS and TRIPLETs ICI
Mario Mandalà
University of Perugia, Santa Maria Misericordia Perugia, Italy
10:35-10:40
Discussion/Q&A
10:40-11:00
What's New in Advanced Melanoma 1st Line - TME-modulating VACCINE
Jessica C. Hassel
University Hospital Heidelberg, Germany
11:00-11:05
Discussion/Q&A
11:05-11:25
What's New in Advanced Melanoma 1st Line - Various Vaccines, New Agents
Olivier Michielin
University Hospital Geneva, Switzerland
11:25-11:30
Discussion/Q&A
11:30-12:00
Coffee Break, Poster Viewing & Visit the Exhibition
12:00-12:30
Industry Sponsored Symposium
12:30-13:00
Industry Sponsored Symposium
13:00-13:30
Lunch Break, Poster Viewing & Visit the Exhibition
13:30-14:15
Session 10: Short Presentations Young Investigators
14:15-15:30
Session 11: What's New in Melanoma 2nd Line: PD-1 Refractory Advanced Melanoma 2nd Line
14:15-14:35
Oncolytic Vaccines
Caroline Robert
Gustave Roussy Cancer Campus, Paris, France
14:35-14:40
Discussion/Q&A
14:40-15:00
TIL Therapy
15:00-15:05
Discussion/Q&A
15:05-15:30
PANEL DISCUSSION 1st and 2nd Line What's New?
15:30-16:00
Poster Award Ceremony, Closing Remarks & End of Congress
Prof. Dr. Alexander M.M. Eggermont, Netherlands and Prof. Dr. Caroline Robert, France | Congress Chairs
16:00
Post-Conference Coffee and Networking
